Changes in Inflammatory and Atherogenesis Biomarkers With the 2-Drug Regimen Dolutegravir Plus Lamivudine in Antiretroviral Therapy–Experienced, Virologically Suppressed People With HIV-1: A Systematic Literature Review

BACKGROUND: The 2-drug regimen dolutegravir plus lamivudine has demonstrated long-term noninferior efficacy vs 3-/4-drug regimens (3/4DRs) in phase 3 trials. This systematic literature review summarizes clinical trial and real-world evidence evaluating impact of dolutegravir plus lamivudine on infla...

Descripción completa

Detalles Bibliográficos
Autores principales: Llibre, Josep M, Cahn, Pedro E, Lo, Janet, Barber, Tristan J, Mussini, Cristina, van Welzen, Berend J, Hernandez, Beatriz, Donovan, Cynthia, Kisare, Michelle, Sithamparanathan, Myooran, van Wyk, Jean
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8900931/
https://www.ncbi.nlm.nih.gov/pubmed/35265729
http://dx.doi.org/10.1093/ofid/ofac068

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8900931/
https://www.ncbi.nlm.nih.gov/pubmed/35265729
http://dx.doi.org/10.1093/ofid/ofac068

Ejemplares similares